BACKGROUND: To our knowledge, the effect of kidney function on successful aging has not been examined. METHODS: We evaluated the relationship between cystatin C and aging success during a 6-year follow-up in the Cardiovascular Health Study, a community-based cohort of older adults (aged >or= 65 years). Successful aging was defined as remaining free of cardiovascular disease, cancer, and chronic obstructive pulmonary disease and having intact physical and cognitive functioning. In adjusted analysis, an accelerated failure time model was used to evaluate the percentage reduction in successful years by level of cystatin C. A separate Cox proportional hazards model evaluated whether cystatin C was related to incident physical and cognitive disability. RESULTS: A total of 2140 participants had cystatin C measured and were free of the previously mentioned conditions at baseline. Their mean age was 74 years. The mean cystatin C level, creatinine level, and estimated glomerular filtration rate were 1.06 mg/L, 0.93 mg/dL, and 78 mL/min/1.73 m(2), respectively (to convert cystatin C to nanomoles per liter, multiply by 75; and to convert creatinine to micromoles per liter, multiply by 88.4). A total of 873 participants reached a first event in follow-up, 138 because of cognitive disability, 238 because of physical disability, 34 because of chronic obstructive pulmonary disease, 146 because of cancer, and 317 because of cardiovascular disease. The adjusted percentage reduction in successful life years in the highest vs the lowest quartile of cystatin C was 27% (95% confidence interval, 11%-39%). The highest vs lowest quartile of cystatin C also was independently associated with incident cognitive or physical disability (hazard ratio, 1.39; 95% confidence interval, 1.00-1.98). CONCLUSION: A higher cystatin C level, even within a range of relatively normal kidney function, was associated with unsuccessful aging.
BACKGROUND: To our knowledge, the effect of kidney function on successful aging has not been examined. METHODS: We evaluated the relationship between cystatin C and aging success during a 6-year follow-up in the Cardiovascular Health Study, a community-based cohort of older adults (aged >or= 65 years). Successful aging was defined as remaining free of cardiovascular disease, cancer, and chronic obstructive pulmonary disease and having intact physical and cognitive functioning. In adjusted analysis, an accelerated failure time model was used to evaluate the percentage reduction in successful years by level of cystatin C. A separate Cox proportional hazards model evaluated whether cystatin C was related to incident physical and cognitive disability. RESULTS: A total of 2140 participants had cystatin C measured and were free of the previously mentioned conditions at baseline. Their mean age was 74 years. The mean cystatin C level, creatinine level, and estimated glomerular filtration rate were 1.06 mg/L, 0.93 mg/dL, and 78 mL/min/1.73 m(2), respectively (to convert cystatin C to nanomoles per liter, multiply by 75; and to convert creatinine to micromoles per liter, multiply by 88.4). A total of 873 participants reached a first event in follow-up, 138 because of cognitive disability, 238 because of physical disability, 34 because of chronic obstructive pulmonary disease, 146 because of cancer, and 317 because of cardiovascular disease. The adjusted percentage reduction in successful life years in the highest vs the lowest quartile of cystatin C was 27% (95% confidence interval, 11%-39%). The highest vs lowest quartile of cystatin C also was independently associated with incident cognitive or physical disability (hazard ratio, 1.39; 95% confidence interval, 1.00-1.98). CONCLUSION: A higher cystatin C level, even within a range of relatively normal kidney function, was associated with unsuccessful aging.
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: Michael G Shlipak; Linda F Fried; Mary Cushman; Teri A Manolio; Do Peterson; Catherine Stehman-Breen; Anthony Bleyer; Anne Newman; David Siscovick; Bruce Psaty Journal: JAMA Date: 2005-04-13 Impact factor: 56.272
Authors: Michael G Shlipak; Linda F Fried; Casey Crump; Anthony J Bleyer; Teri A Manolio; Russell P Tracy; Curt D Furberg; Bruce M Psaty Journal: Kidney Int Date: 2002-09 Impact factor: 10.612
Authors: Michael G Shlipak; Linda F Fried; Casey Crump; Anthony J Bleyer; Teri A Manolio; Russell P Tracy; Curt D Furberg; Bruce M Psaty Journal: Circulation Date: 2003-01-07 Impact factor: 29.690
Authors: Yelena Slinin; Katherine W Peters; Areef Ishani; Kristine Yaffe; Howard A Fink; Katie L Stone; Michael Steffes; Kristine E Ensrud Journal: J Gerontol A Biol Sci Med Sci Date: 2014-11-01 Impact factor: 6.053
Authors: Robert C Kalayjian; Kevin R Robertson; Jeffrey M Albert; Carl J Fichtenbaum; Todd T Brown; Babafemi O Taiwo Journal: J Acquir Immune Defic Syndr Date: 2019-06-01 Impact factor: 3.731
Authors: Allyson Hart; Misti L Paudel; Brent C Taylor; Areef Ishani; Eric S Orwoll; Peggy M Cawthon; Kristine E Ensrud Journal: J Am Geriatr Soc Date: 2013-09-03 Impact factor: 5.562
Authors: Lorien S Dalrymple; Ronit Katz; Dena E Rifkin; David Siscovick; Anne B Newman; Linda F Fried; Mark J Sarnak; Michelle C Odden; Michael G Shlipak Journal: Clin J Am Soc Nephrol Date: 2013-10-31 Impact factor: 8.237
Authors: Cassianne Robinson-Cohen; Ronit Katz; Dariush Mozaffarian; Lorien S Dalrymple; Ian de Boer; Mark Sarnak; Mike Shlipak; David Siscovick; Bryan Kestenbaum Journal: Arch Intern Med Date: 2009-12-14
Authors: Carmen A Peralta; Anne Lee; Michelle C Odden; Lenny Lopez; Adina Zeki Al Hazzouri; John Neuhaus; Mary N Haan Journal: J Am Geriatr Soc Date: 2012-12-18 Impact factor: 5.562